A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 12, 2012, Pages 927-933

  Tofteland, Ståle ^a   Dahl, Kristin H ^b,c   Aasnæs, Bettina ^b   Sundsfjord, Arnfinn ^b,c   Naseer, Umaer ^b,c  

^a Sørlandet Hospital Health Enterprise   (Norway)

^b Reference Centre for Detection of Antimicrobial Resistance   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Chromosomal ampC hyperproducing E. coli; National epidemiology; OXY 2 hyperproducing K. oxytoca

Indexed keywords

BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; CEFPODOXIME; EXTENDED SPECTRUM BETA LACTAMASE; OUTER MEMBRANE PROTEIN F;

ANTIBIOTIC SENSITIVITY; ARTICLE; EPSILOMETER TEST; ESCHERICHIA COLI; ISOELECTRIC FOCUSING; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; DNA, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENES, BACTERIAL; HUMANS; ISOELECTRIC FOCUSING; KLEBSIELLA; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TESTS; NORWAY; POLYMERASE CHAIN REACTION;

EID: 84874166213     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.707330     Document Type: Article

References (33)

1. NORM/NORM-VET 2000. U sage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Troms ø, Oslo; 2001. Available at: http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report (accessed July 2012).
2. NORM/NORM-VET 2010. U sage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Troms ø, Oslo; 2011. Available at: http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report (accessed July 2012).
3. Naseer U, Sundsfjord A. T he CTX-M conundrum: Dissemination of plasmids and Escherichia coli clones. Microb Drug Resist 2011; 17: 83-97.
4. Livermore DM, Woodford N. T he beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-20.
5. Livermore D M. b eta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
6. Mulvey M R, Bryce E, Boyd D A, Ofner-Agostini M, Land AM, Simor AE, et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005; 49: 358-65.
7. Clarke B, Hiltz M, Musgrave H, Forward KR. C ephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada. Emerg Infect Dis 2003; 9: 1254-9.
8. M ammeri H, E b F, Berkani A, Nordmann P. M olecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J Antimicrob Chemother 2008; 61: 498-503.
9. Jø r gensen R L, Nielsen J B, Friis-Mø l ler A, Fjelds øe -Nielsen H, Schonning K. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J Antimicrob Chemother 2010; 65: 460-4.
10. Haldorsen B, Aasnaes B, Dahl KH, Hanssen AM, Simonsen GS, Walsh TR, et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008; 62: 694-702.
11. Bogaerts P, Rodriguez-Villalobos H, Bauraing C, Deplano A, Laurent C, Berhin C, et al. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals. Pathol Biol (Paris) 2010; 58: 78-83.
12. Gheorghiu R, Yuan M, Hall L M, Livermore DM. B ases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase. J Antimicrob Chemother 1997; 40: 533-41.
13. Mammeri H, Poirel L, Nordmann P. I n vivo selection of a chromosomally encoded beta-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca. Antimicrob Agents Chemother 2003; 47: 3739-42.
14. Kallman O, Giske CG, Samuelsen O, Wretlind B, Kalin M, Olsson-Liljequist B. Interplay of effl ux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli. Microb Drug Resist 2009; 15: 91-5.
15. Schumacher H, Skibsted U, Skov R, Scheibel J. C efuroxime resistance in Escherichia coli. Resistance mechanisms and prevalence. APMIS 1996; 104: 531-8.
16. L ee CH, Chia JH, Chu C, W u TL, Liu JW, S u LH. I n vivo selection of OmpK35-defi cient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae. J Antimicrob Chemother 2006; 58: 857-60.
17. Domenech-Sanchez A, Martinez-Martinez L, Hernandez-Alles S, del Carmen Conejo M, Pascual A, Tomas JM, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 2003; 47: 3332-5.
18. Schumacher H, Skibsted U, Hansen D S, Scheibel J. C efuroxime resistance in Klebsiella pneumoniae. Susceptibility to cefotaxime and ceftazidime despite production of ESBLs. APMIS 1997; 105: 708-16.
19. Nelson EC, Segal H, Elisha BG. O uter membrane protein alterations and blaTEM-1 variants: Their role in beta-lactam resistance in Klebsiella pneumoniae. J Antimicrob Chemother 2003; 52: 899-903.
20. Kallman O, Fendukly F, Karlsson I, Kronvall G. C ontribution of effl ux to cefuroxime resistance in clinical isolates of Escherichia coli. Scand J Infect Dis 2003; 35: 464-70.
21. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, aplasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
22. Doumith M, Ellington M J, Livermore D M, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
23. Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006; 42: E95-8.
24. Martinez-Martinez L, Pascual A, Hernandez-Alles S, Alvarez-Diaz D, Suarez AI, Tran J, et al. Roles of betalactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999; 43: 1669-73.
25. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008; 32: 534-7.
26. Palasubramaniam S, Subramaniam G, Muniandy S, Parasakthi N. Extended-spectrum beta-lactam resistance due to AmpC hyperproduction and CMY-2 coupled with the loss of OMPK35 in Malaysian strains of Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2007; 13: 186-90.
27. Webster DP, Gaulton T, Woodford N, Pike R, Turton J, Perry C, et al. Emergence of carbapenem resistance due to porin loss in an extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy. Int J Antimicrob Agents 2010; 36: 575-6.
28. Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin - tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 362-7.
29. Weber DA, Sanders CC, Bakken JS, Quinn JP. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis 1990; 162: 460-5.
30. Wu TL, Siu LK, S u LH, Lauderdale TL, Lin FM, Leu HS, et al. Outer membrane protein change combined with co-existing TEM-1 and SHV-1 beta-lactamases lead to false identifi cation of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother 2001; 47: 755-61.
31. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of CMY-2-producing multidrugresistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2010; 16: 171-8.
32. Tofteland S, Haldorsen B, Dahl K H, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrumbeta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007; 45: 199-205.
33. NORM/NORM-VET 2004. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway.